PURPOSE: Survivors of childhood acute lymphoblastic leukemia (ALL) treated with CNS-directed chemotherapy are at risk for neurocognitive deficits. Prospective longitudinal studies are needed to clarify the neurodevelopmental trajectory in this vulnerable population. METHODS: Patients enrolled in the St. Jude Total Therapy Study XV, which omitted prophylactic cranial radiation therapy in all patients, completed comprehensive neuropsychological assessments at induction (n = 142), end of maintenance (n = 243), and 2 years after completion of therapy (n = 211). We report on longitudinal change in neurocognitive function and predictors of neurocognitive outcomes 2 years after completing therapy. RESULTS: Neurocognitive function was largely age appropriate 2 years after completing therapy; however, the overall group demonstrated significant attention deficits and a significantly greater frequency of learning problems as compared with national normative data (all P ≤ .005). Higher-intensity CNS-directed chemotherapy conferred elevated risk for difficulties in attention, processing speed, and academics (all P ≤ .01). The rate and direction of change in performance and caregiver-reported attention difficulties differed significantly by age at diagnosis and sex. End-of-therapy attention problems predicted lower academic scores 2 years later, with small to moderate effect sizes (│r│= 0.17 to 0.25, all P ≤ .05). CONCLUSION: Two years after chemotherapy-only treatment, neurocognitive function is largely age appropriate. Nonetheless, survivors remain at elevated risk for attention problems that impact real-world functioning. Attention problems at the end of therapy predicted decreased academics 2 years later, suggesting an amplified functional impact of discrete neurocognitive difficulties. Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols.
PURPOSE: Survivors of childhood acute lymphoblastic leukemia (ALL) treated with CNS-directed chemotherapy are at risk for neurocognitive deficits. Prospective longitudinal studies are needed to clarify the neurodevelopmental trajectory in this vulnerable population. METHODS:Patients enrolled in the St. Jude Total Therapy Study XV, which omitted prophylactic cranial radiation therapy in all patients, completed comprehensive neuropsychological assessments at induction (n = 142), end of maintenance (n = 243), and 2 years after completion of therapy (n = 211). We report on longitudinal change in neurocognitive function and predictors of neurocognitive outcomes 2 years after completing therapy. RESULTS: Neurocognitive function was largely age appropriate 2 years after completing therapy; however, the overall group demonstrated significant attention deficits and a significantly greater frequency of learning problems as compared with national normative data (all P ≤ .005). Higher-intensity CNS-directed chemotherapy conferred elevated risk for difficulties in attention, processing speed, and academics (all P ≤ .01). The rate and direction of change in performance and caregiver-reported attention difficulties differed significantly by age at diagnosis and sex. End-of-therapy attention problems predicted lower academic scores 2 years later, with small to moderate effect sizes (│r│= 0.17 to 0.25, all P ≤ .05). CONCLUSION: Two years after chemotherapy-only treatment, neurocognitive function is largely age appropriate. Nonetheless, survivors remain at elevated risk for attention problems that impact real-world functioning. Attention problems at the end of therapy predicted decreased academics 2 years later, suggesting an amplified functional impact of discrete neurocognitive difficulties. Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols.
Authors: Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: Wilburn E Reddick; Zuyao Y Shan; John O Glass; Susan Helton; Xiaoping Xiong; Shengjie Wu; Melanie J Bonner; Scott C Howard; Robbin Christensen; Raja B Khan; Ching-Hon Pui; Raymond K Mulhern Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Annemieke I Buizer; Leo M J De Sonneville; Marry M van den Heuvel-Eibrink; Charles Njiokiktjien; Anjo J P Veerman Journal: J Int Neuropsychol Soc Date: 2005-09 Impact factor: 2.892
Authors: Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: M Jankovic; P Brouwers; M G Valsecchi; A Van Veldhuizen; J Huisman; R Kamphuis; A Kingma; W Mor; J Van Dongen-Melman; L Ferronato Journal: Lancet Date: 1994-07-23 Impact factor: 79.321
Authors: N von der Weid; I Mosimann; A Hirt; P Wacker; M Nenadov Beck; P Imbach; U Caflisch; F Niggli; A Feldges; H P Wagner Journal: Eur J Cancer Date: 2003-02 Impact factor: 9.162
Authors: Kathleen C Insel; Marilyn J Hockenberry; Lynette L Harris; Kari M Koerner; Zhenqiang Lu; Kristin B Adkins; Olga A Taylor; Patricia M Gundy; Ida M Moore Journal: Oncol Nurs Forum Date: 2017-07-01 Impact factor: 2.172
Authors: Lisa M Jacola; Kim Edelstein; Wei Liu; Ching-Hon Pui; Robert Hayashi; Nina S Kadan-Lottick; Deokumar Srivastava; Tara Henderson; Wendy Leisenring; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Lancet Psychiatry Date: 2016-09-14 Impact factor: 27.083
Authors: Heather M Conklin; Jason M Ashford; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Robert J Ogg; Sima Jeha; Lu Huang; Hui Zhang Journal: J Pediatr Psychol Date: 2017-03-01
Authors: Matthew J Ehrhardt; Daniel A Mulrooney; Chenghong Li; Malek J Baassiri; Kari Bjornard; John T Sandlund; Tara M Brinkman; I-Chan Huang; Deo Kumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Date: 2017-09-15 Impact factor: 6.860
Authors: Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544